NCT01433965View on ClinicalTrials.gov

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 8, 2012

Primary Completion Date

June 12, 2018

Study Completion Date

January 12, 2021

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Lenalidomide

Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.

Trial Locations (1)

95817

University of California Davis, Sacramento

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

University of California, Davis

OTHER